DnaJ heat shock protein family (Hsp40) member C19Genealiases: PAM18 · TIM14 · TIMM14
Q-omics provides the consensus-scored DNAJC19 profile across patient tissues and cancer cell-line models. DNAJC19 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, DNAJC19 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, DNAJC19 protein abundance shows 24,454 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, KIRP, and LSCC as cancer lineages where DNAJC19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC19 survival associations across molecular data types. DNAJC19 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC19 RNA expression–survival associations across cancer types. High DNAJC19 expression shows unfavorable associations in PAAD, LGG, SCLC and UCEC, but favorable associations in BRCA and LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for DNAJC19 RNA expression.
This table summarizes DNAJC19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAJC19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC19 shows lower tumor expression in KIRP, THCA, KIRC and KICH and higher tumor expression in HNSC and LUSC. The KIRP box plot shows higher DNAJC19 RNA expression in normal versus tumor tissue (log2 FC = −1.080, t-test p < 0.001).
This table shows molecular features associated with DNAJC19 in patient tissues and cancer cell lines. In patient samples, DNAJC19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
